Allogeneic bone marrow transplantation was initially considered as a means of delivering supralethal doses of chemotherapy and total body irradiation (TBI) for the treatment of malignancy (Thomas, 1969 (Thomas, , 1983 . Many malignancies exhibit a steep dose±response relationship to chemo-or radiotherapy, with higher doses producing greater cytoreduction. Bone marrow transplantation (BMT) enables the escalation of doses of many agents beyond those producing severe bone marrow toxicity. The marrow transplant was considered a supportive care modality to restore haematopoiesis. It has become clear, however, that the high-dose therapy does not eradicate the malignancy in many patients and that the therapeutic benefit of allogeneic marrow transplantation is largely related to an associated immune-mediated graft-versusmalignancy effect.
Graft-versus-malignancy
Extensive clinical and experimental data support the presence of graft-versus-malignancy effects (see Table I ). Most relate to allogeneic transplantation for leukaemia, graft-versus-leukaemia or -lymphoma (GVL) effects. There is a reduced risk of leukaemia relapse in patients with acute and chronic graft-versus-host disease (Weiden et al, 1979 (Weiden et al, , 1981 Sullivan et al, 1989; Horowitz et al, 1990) . There is a higher risk of relapse after syngeneic bone marrow transplantation (Gale & Champlin, 1984; Fefer et al, 1986; Gale et al, 1994) and after T-cell-depleted allotransplants (Horowitz et al, 1990; Marmont et al, 1991) . This indicates that minimal residual disease is present in many patients after transplant which can lead to relapse if GVL is not present.
The most striking and direct evidence supporting the concept of GVL is the observation that many patients who relapse after allogeneic transplantation can be reinduced into complete remission by infusing additional donor lymphocytes (Cullis et al, 1992; Antin, 1993; Drobyski et al, 1993; Van Rhee et al, 1994; Kolb et al, 1995; Mackinnon et al, 1995) . After engraftment of an allogeneic transplant, immune reconstitution generally occurs exclusively from donor-derived immunocompetent cells. In patients who relapse, there is ineffective immune suppression of the malignancy. This may be in part because of immunosuppressive therapy, an inadequate number of cytotoxic precursors in the original graft or induction of tolerance after transplant. This unresponsive state can often be overcome by infusion of additional donor lymphocytes capable of responding against the malignant cells.
Disease susceptibility to graft-versus-malignancy There are major differences among malignancies in their susceptibility to GVL effects. The risk of relapse is increased by approximately threefold with syngeneic transplants versus transplants from matched siblings in both acute myeloid leukaemia (AML) and chronic myeloid leukaemia (CML), suggesting that allogeneic target antigens are involved (Horowitz et al, 1990) . T lymphocytes appear most important in CML, in which T-cell-depleted transplants are associated with a fivefold increase in the risk of leukaemia relapse (Apperley et al, 1986a; Goldman et al, 1988; Horowitz et al, 1990; Marmont et al, 1991; Mackinnon et al, 1994) . Minimal residual disease can be detected during the first 6 months after high-dose chemoradiotherapy and allogeneic bone marrow transplantation in the majority of patients with CML using cytogenetic or polymerase chain reaction-based techniques (Apperley et al, 1986b; Offit et al, 1990; Sawyers et al, 1990; DeLage et al, 1991; Hughes et al, 1991; Lee et al, 1992; Pichert & Ritz, 1993; Pichert et al, 1994; Radich et al, 1995; Rapanotti et al, 1997) . Malignant cells become undetectable in most patients receiving unmodified (T-cell replete) marrow transplants, presumably because of the GVL effect. In patients receiving a syngeneic or T-cell-depleted BMT (where GVL may not occur), residual leukaemia cells generally proliferate, producing relapse.
Approximately 70% of CML patients relapsing into chronic phase achieve complete remission after donor lymphocyte infusion (Cullis et al, 1992; Antin, 1993; Drobyski et al, 1993; Kolb et al, 1995; Bacigalupo et al, 1997; Collins et al, 1997; Raanani et al, 1997) . Similar results have been achieved with HLA-identical sibling or matched unrelated donors . The best results occur with relapses into chronic phase and when infusions are administered early in the course of relapse (Van Rhee et al, 1994; Dazzi et al, 1999) . In responding patients, residual leukaemia becomes undetectable by polymerase chain reaction analysis for bcr±abl rearrangement, and these responses are generally durable.
In AML, there is a major GVL effect evidenced by the threefold risk of relapse with syngeneic transplants (Gale & Champlin, 1984; Gale et al, 1994) . The relapse rate is only minimally affected by T-cell depletion, and natural killer cells have been suggested as mediators of antileukaemic activity (Marmont et al, 1991; Papadopoulos et al, 1998) . Approximately one-third of AML or myelodysplasia patients respond to donor lymphocyte infusions, but these remissions are generally transient and patients typically relapse within the following year (Kolb et al, 1995; Okumura et al, 1996; Porter et al, 1996; Collins et al, 1997) .
Among the major leukaemias, acute lymphocytic leukaemia (ALL) appears least affected by GVL (Horowitz et al, 1990; Marmont et al, 1991; Gale et al, 1994) , possibly because of the pace of the disease or the lack of costimulatory molecules and limited capacity of the leukaemic lymphoblasts to stimulate an effective immune response (Brenner & Porcelli, 1997; Cardoso et al, 1997) . Only a few patients with ALL have responded to donor lymphocyte infusions.
Relatively few patients have received allogeneic transplants for indolent lymphoid malignancies [low-grade lymphoma and chronic lymphocytic leukaemia (CLL)], but available data indicate that potent graft-versus-malignancy effects occur against these disorders. Selected patients with CLL (Rondo Ân et al, 1996) and lymphoma Michallet et al, 1996; Van Besien et al, 1997 have also responded to donor lymphocyte infusions or modification of immunosuppressive therapy. Approximately one-third of patients with multiple myeloma (Tricot et al, 1996; Lokhorst et al, 1997) respond to donor lymphocyte infusions, but these responses are usually transient.
A major question is whether graft-versus-tumour effects occur against solid tumours. Pilot studies in breast cancer have reported anti-tumour responses in patients with graftversus-host disease, suggesting a graft-versus-adenocarcinoma effect (Eibl et al, 1996; Ueno et al, 1998) . Limited data suggest graft-versus-tumour effects against renal cell cancer, breast cancer and potentially other malignancies (Ueno et al, 1998; Childs et al, 1999a,b) . Further studies are required to determine whether a clinically meaningful graftversus-tumour effect will occur in order to justify the added morbidity related to allogeneic transplantation.
Mechanism of graft-versus-malignancy effects
Graft-versus-malignancy responses may occur coincidentally with graft-versus-host disease (GVHD). However, many patients achieve a GVL response, i.e. remission of their leukaemia after donor lymphocyte infusion without developing GVHD. Although this is consistent with the premise that different target antigens may be involved with each process, it could also result from a greater sensitivity of malignant cells than visceral tissues to a common immunological mechanism. Graft-versus-leukaemia/lymphoma activity could be a result of reactivity against haematopoietic lineage-related antigens or leukaemia-specific targets. Minor histocompatibility antigens restricted to haematopoietic tissues have been described previously (Falkenburg et al, 1991; Goulmy et al, 1991; Warren et al, 1998; Bonnett et al, 1999; Clave et al, 1999; Mutis et al, 1999) . Overexpressed or abnormally expressed cellular constituents could also serve as target antigens for GVL. Proteinase 3, a serine protease present in myeloid primary granules, is overexpressed in CML and in some cases of AML; it may serve as a target for an antileukaemic immune response. Peptide antigens derived from proteinase 3 can stimulate the generation of autologous or allogeneic T-cell cytotoxicity against the leukaemias (Molldrem et al, , 1997 . Thus, graft-versus-malignancy could involve broad reactivity overlapping with GVHD or restricted antihaematopoietic or disease-specific reactivity (Fig 1) . The potential target antigens for graft-versus-solid tumour effects are unknown. Further studies are required to Table I . Clinical evidence supporting an allogeneic graft-versus-leukaemia effect against haematological malignancies.
Demonstration of minimal residual disease after high-dose therapy which is slowly eliminated in T-cell-replete allogeneic transplants Demonstration of reactivity of donor derived T-cell clones against malignant cells Reduced risk of relapse in patients with GVHD Increased risk of relapse after syngeneic transplants Increased risk of relapse after T-cell-depleted transplants Induction of remission by donor lymphocyte infusion in patients relapsing after BMT Induction of remission after non-ablative preparative regimen Fig 1. After haematopoietic transplantation from an HLA-identical sibling, graft-versus-malignancy effects may potentially be mediated against minor histocompatibility antigens expressed broadly by host tissues (overlapping targets of GVHD), antigens restricted to haematopoietic tissues (graft-versus-haematopoietic effect) or malignancy-specific targets. This process does not usually appear to be malignancy specific as T-cell clones from allogeneic transplant recipients generally react against normal host-derived haematopoietic cells as well as the malignancy. Clinically, malignancy-specific reactivity can rarely be demonstrated after allogeneic haematopoietic transplantation. Donor-derived T-cell clones from allogeneic chimaeras typically react against both host normal haematopoietic cells and the leukaemia (Sosman et al, 1990; Jiang et al, 1991; Faber et al, 1995) . Host-derived normal and malignant cells are generally both eliminated, and responding patients generally become complete chimaeras in conjunction with or before the anti-tumour response (Childs et al, 1999b) .
Effector cells of graft-versus-malignancy
The effector cells involved with GVHD and GVL are incompletely defined. Both CD4 1 and CD8 1 T cells participate in the initiation of GVHD; other cell populations, including natural killer (NK) cells, are subsequently recruited and cytokines participate as mediators of tissue injury (Korngold & Sprent, 1987a,b; Ferrara et al, 1989 Ferrara et al, , 1993 Ferrara & Deeg, 1991; Sakamoto et al, 1991) . In animal models of graft-versus-leukaemia, both CD4
1 and CD8 1 effectors have been described. In most systems, CD8-positive cells appear to be the principal effectors of GVL (Truitt & Atasoylu, 1991; Okunewick et al, 1991 Okunewick et al, , 1995 Faber et al, 1992 Faber et al, , 1995 Van der Harst et al, 1994) . In human BMT recipients, both CD4
1 and CD8 1 cytotoxic antileukaemic T-cell lines or clones have been described. In patients transplanted for CML, several recent studies have identified CD4
1 T-cell lines or clones that either inhibit the growth of leukaemia progenitors or are directly lytic (Sosman et al, 1990; Van der Harst et al, 1994; Jiang & Barrett, 1995; Jiang et al, 1996) . Natural killer cells have also been implicated as mediators of GVL effects (Hauch et al, 1990; Okunewick et al, 1995; Zeis et al, 1995; Glass et al, 1996; Jiang et al, 1997) .
Donor lymphocyte infusions (DLI)
In patients relapsing after allogeneic haematopoietic transplantation, the malignancy typically recurs in hostderived cells, but residual normal haematopoiesis and immunity remain largely donor derived. The infused donor lymphocytes are therefore not rejected, but acute GVHD may develop. In initial studies, patients generally received large doses of T cells, generally . 5 Â 10 7 T cells/kg, and acute GVHD developed in . 50% of cases, with mortality in up to 20% of recipients (Antin, 1993; Drobyski et al, 1993) . There is initially little change in the peripheral blood count after infusion of donor lymphocytes, but after a median of 4 months responding patients may suddenly become hypoplastic, followed by recovery from donorderived haematopoietic cells and a return to complete chimaerism (Giralt & Champlin, 1994; Kolb et al, 1995; Collins et al, 1997) . Antileukaemic effectors presumably proliferate in vivo after the infusion, and presumably must reach a threshold level to eradicate the leukaemia and normal haematopoietic cells that are host derived (Hoffmann et al, 1993) . Marrow aplasia may occur unless sufficient donor-derived normal progenitors are present to restore haematopoiesis (Keil et al, 1997) . Consistent with this premise, CML patients with advanced relapse more frequently develop marrow aplasia than patients treated in cytogenetic or early haematological relapse (Van Rhee et al, 1994; Keil et al, 1997) . Patients developing aplasia generally recover after a second infusion of donor haematopoietic stem cells from either marrow or mobilized peripheral blood. A critical factor after donor lymphocyte infusion is the kinetics of growth of the leukaemia; rapid regrowth may outpace the development of an effective immune antileukaemic response.
Separation of graft-versus-malignancy from GVHD
A major challenge is to separate the beneficial GVL effect from the adverse manifestations of graft-versus-host disease. A number of approaches have been studied, as indicated in Table II . Both GVHD and GVL are T-cell-related processes. The pathophysiology of GVHD is complex. Although T cells are necessary to initiate the process, inflammatory cytokines play a major role, and inhibition of cytokine generation early after transplant could suppress the manifestations of GVHD while allowing later cell-mediated antileukaemic responses to occur (Ferrara & Deeg, 1991; Hill et al, 1998) .
There is a dose±response effect with higher rates of GVHD as well as anti-leukaemia responses with increasing doses of T cells (Mackinnon et al, 1995) . MacKinnon et al (1995) performed a study administering graded doses of T cells to patients with CML relapsing into chronic phase after an allogeneic transplant from an HLA-identical sibling. A starting dose of 1 Â 10 5 T cells/kg was administered. Patients failing to respond received progressively higher doses after a median of 2 months. Antileukaemic responses and GVHD did not occur at doses of 1 Â 10 5 25 Â 10 6 T cells/kg. Of 21 patients receiving 1 Â 10 7 T cells/kg, eight patients achieved complete remission (CR) and only one developed acute GVHD. At higher doses there were additional responses, but a much increased risk of GVHD. Thus, it may be possible to induce antileukaemic responses Table II . Strategies for generating non-alloreactive T cells for separation of graft-versus-malignancy from GVHD.
Administer graded doses of T cells below threshold to produce GVHD Inhibit inflammatory cytokines mediating GVHD Deplete GVHD effectors T-cell subset depletion Deplete cells activated in mixed lymphocyte culture Induce anergy
Blockade of co-stimulation Prevent T-cell proliferation by sublethal radiation, psoralens or toxins Anti-third party T cells Transduce T cells with suicide gene (HSV-TK) Combine stem cells with antigen-specific T cells Anti-haematopoietic minor, anti-infection, anti-malignancy at a T-cell dose below the threshold necessary to product GVHD. This general approach has been confirmed by others (Bacigalupo et al, 1997; Rahman et al, 1998 ). An alternative strategy is to infuse T-cell subpopulations that can mediate GVL with a reduced potential for GVHD. Selective depletion of CD8-positive cells from the allogeneic donor marrow transplants reduces the incidence of GVHD without increasing the risk of relapse in CML (Champlin et al, 1990 Nimer et al, 1994) . Donor lymphocyte infusions using CD8-depleted cells have also been effective in reinducing remission in patients with CML with a low rate of GVHD (Giralt et al, 1995; Alyea et al, 1998) . At the MD Anderson Cancer Center, 24 patients with CML received CD8-depleted DLI from their original transplant donor for the treatment of relapse (Shimoni et al, 1999) . The DLI contained a median of 3 Â 10 7 CD4 1 cells/kg and contained less then 0´3 Â 10 6 CD8 1 cells/kg. Cells were obtained from HLA-matched siblings in 18 cases and HLAmatched unrelated donors in six cases. Nine patients had received T-cell-depleted original transplants. Fourteen patients achieved a complete haematological and cytogenetic response, including 13 out of 15 patients in cytogenetic or haematological relapse. Only one out of nine patients with accelerated or blastic phase achieved remission. Five patients developed acute and/or chronic GVHD, two patients had acute GVHD and four patients had chronic GVHD. Two patients died of infection or chronic GVHD. At a median follow-up of 34 months (range 9±69 months), 10 of the 15 patients with early phase relapse are alive in remission. Only one responder relapsed and is undergoing further treatment. Further study is required to determine the optimal cell dose and to compare the relative effectiveness of CD8-depleted DLI with graded doses of unfractionated lymphocytes.
GVHD is initiated by alloreactive T cells. A novel strategy to prevent GVHD is to induce anergy in the donor T-cell population against recipient alloantigens. Guinan et al (1999) reported success by co-cultivating donor and recipient cells with CTLA-4Ig, blocking co-stimulation via the B7-CD28 pathway. In a preliminary study, this approach was successful in allowing engraftment and manageable GVHD with haploidentical transplants. Another strategy is to transduce donor T cells with a suicide gene, such as herpes simplex virus thymidine kinase (TK), which confers sensitivity to ganciclovir treatment. The viral thymidine kinase phosphorylates ganciclovir into a monophosphate that is subsequently converted by cellular kinases into the cytotoxic triphosphate form. In preliminary studies, TKtransduced lymphocytes were capable of alloreactivity, resulting in GVL effects. If the patient develops GVHD, it can be abrogated by ganciclovir treatment, lysing the transduced lymphocytes. This approach has been successful in pilot studies using TK-transduced T cells for donor lymphocyte infusions (Bonini et al, 1997) or combining TKtransduced lymphocytes with T-cell-depleted marrow transplants (Tiberghien et al, 1994; Munshi et al, 1997) . In each setting, acute GVHD could be successfully treated with ganciclovir. Ganciclovir treatment may also abrogate GVL effects, and it is uncertain whether this strategy will improve leukaemia-free survival. The ex vivo transduction and expansion procedure may change the composition and immune reactivity of the cells, and initial studies suggest that the transduced cells appear less alloreactive, requiring higher cell doses to produce both GVL and GVHD . This approach requires further evaluation in animal models as well as definitive testing in human clinical trials. Combination of these suicidal lymphocytes with Tcell-depleted haematopoietic stem cells could prevent resistant GVHD and markedly improve the safety of allogeneic transplantation.
Ex vivo depletion of alloreactive T cells is another potential approach for separating GVL from GVHD. Alloreactive cells stimulated in a mixed lymphocyte culture can be depleted by treatment of the cells with an immunotoxin-targeting an activation antigen, such as the interleukin 2 receptor (Cavazzana-Calvo et al, 1994; Mavroudis et al, 1998; Garderet et al, 1999) . The remaining non-activated cells have a reduced potential to produce GVHD, yet may retain reactivity against infectious organisms and, possibly, the malignancy. Human studies are needed to determine whether this approach will reduce the incidence of GVHD and provide beneficial immune activity.
An alternative strategy involves generation of nonalloreactive cells. A number of approaches have been studied. T cells raised against third party antigens may facilitate engraftment and possibly provide limited immune reconstitution (Bachar-Lustig et al, 1999). Sublethal treatment of allogeneic lymphocytes by radiation or psoralens has been proposed to prevent their proliferation, but to allow survival and retention of some function. These cells may be capable of facilitating engraftment, mediating antitumour effects or restoring limited immune function without producing GVHD (Truitt et al, 1999; Waller et al, 1999 ).
An ideal cellular therapy would consist of leukaemiaspecific effectors devoid of graft-versus-host activity. T-cell clones or lines have been successfully used for treatment of Epstein±Barr virus (Rooney et al, 1995) and cytomegalovirus (Walter et al, 1995) infections after allogeneic bone marrow transplantation. Smit et al (1998) reported a single case of a patient with CML who relapsed after allogeneic transplantation and failed to respond to donor lymphocyte infusions. This patient was treated with infusion of T-cell lines raised against the leukaemia and achieved a complete response without development of GVHD. The technology for development of therapeutic T-cell clones is demanding and this approach is not sufficiently developed to allow for largescale clinical trials. As an alternative strategy, cytotoxic T lymphocytes specific for malignancy-related antigens could be selected, expanded and parenterally administered as adoptive cellular therapy.
Non-myeloablative preparative regimens
The high-dose chemotherapy and radiation typically used as the preparative regimen for blood stem cell or bone marrow transplantation produces considerable morbidity and mortality. These regimens have been developed to maximize dose intensity, escalating the dose-limiting toxicity in nonhaematopoietic tissues. This approach must be restricted to q 2000 Blackwell Science Ltd, British Journal of Haematology 111: 18±29 young patients who are in good general medical condition. Unfortunately, the majority of patients with haematological malignancies are not eligible for high-dose therapy because of increasing age or medical co-morbidities. An alternate strategy is to utilize a less intensive preparative regimen designed not to eradicate the malignancy but to provide sufficient immunosuppression to achieve engraftment of an allogeneic blood stem cell or marrow graft, thus allowing the development of an immune graft-versus-malignancy effect.
These reduced toxicity regimens are frequently termed non-myeloablative. As a working definition, a truly nonmyeloablative regimen should allow relatively prompt haematopoietic recovery (, 28 d) without a transplant, and upon engraftment after haematopoietic transplantation mixed chimaerism generally occurs. Conversely, an ablative regimen requires haematopoietic transplantation for prompt recovery and complete chimaerism occurs upon engraftment. These lower dose preparative regimens depend on the activity of donor T cells to achieve engraftment. Initial studies focused on patients with an HLA-matched sibling. More intensive regimens are required for engraftment in settings of greater genetic disparity, including unrelated donor transplants, and in HLA-non-identical donor±recipi-ent pairs.
We (Giralt et al, 1997a; Khouri et al, 1998; Ribas et al, 1999) and others (Storb et al, 1997; Slavin et al, 1998) have evaluated this non-myeloablative transplant strategy by using sublethal doses of chemotherapy and/or radiation as the preparative regimen. The treatment scheme is illustrated in Fig 2. The non-ablative regimen is selected to have some activity against the patient's malignancy, but is primarily given to provide sufficient immunosuppression to prevent graft rejection, allowing development of a graft-versusmalignancy effect. This`non-ablative' regimen does not completely eliminate host-derived cells, but allogeneic T cells act to eliminate residual haematopoietic and malignant cells. This process takes months to complete and patients may receive additional donor lymphocytes as necessary to augment the graft-versus-malignancy effects. We have studied chemotherapy regimens with activity against the patient's malignancy that are only modestly myelosuppressive. These less toxic`non-ablative' regimens can be studied in patients considered ineligible for myeloablative preparative regimens because of advanced age or co-morbidities. This approach reduces drug toxicity and may also reduce the risk for severe acute GVHD as the clinical manifestations partly result from the toxicity of the preparative regimen and subsequent cytokine release in addition to the alloreactivity of the graft (Antin & Ferrara, 1992; Hill et al, 1997) . Infectious complications could also be reduced because the non-ablative preparative regimen does not completely eliminate host-derived immunocompetent cells. (Giralt et al, 1997a) or chemotherapy-sensitive AML (Giralt et al, 1997b) . Fludarabine 25±30 mg/m 2 for 4±5 d plus cyclophosphamide in doses $ 1 g/m 2 /d for 2 d has been effective in achieving engraftment in a range of malignancies (Carella et al, 1998; Khouri et al, 1998) .
In a follow-up of the initial study (Giralt et al, 1997b) , 36 patients, aged 55±75 years, with acute myeloid leukaemia, myelodysplasia or chronic myeloid leukaemia were treated with the fludarabine, cytarabine and idarubicin regimens, followed by allogeneic haematological transplantation from an HLA-matched or one antigen-mismatched sibling donor. Patients with residual or recurrent disease received DLI or second non-ablative transplants. Ninety-one per cent of patients had engraftment with donor-derived cells. Treatment-related mortality was 20^7%. Acute GVHD grade 2±4 developed in 32^9%, and 52^14% of patients developed chronic GVHD. Eighty-eight per cent of patients achieved complete remission. Fourteen patients are alive with a median follow-up of 11´5 months (range 4±40) and 13 patients are currently disease free. The projected survival of patients who were in remission or had less then 10% bone marrow blasts at the time of transplant was 71 1 11% and 59 1 14% at 1 year and 2 years respectively. The current disease-free survival is 65^12% and 52^15% at 1 and 2 years. The outcome of patients with refractory disease at transplant is poor, , 10% remained in remission at 1 year. These data indicate that non-myeloablative Recipients (R) receive a relatively non-toxic preparative regimen designed primarily to achieve engraftment of an allogeneic haematopoietic cell transplant (HSCT) for the purpose of inducing a graft-versus-malignancy effect. A short course of immunosuppressive treatment is given to prevent GVHD. Initially, mixed chimaerism is present with co-existence of donor (D) cells with recipient-derived normal (R) and leukaemia (R L ) cells. Recipient and donor patterns of restriction fragment length polymorphisms are shown. Donor-derived T cells act to eradicate residual recipientderived normal and malignant haematopoietic cells leading to complete chimaerism and remission. Donor lymphocyte infusions (DLI) may be administered to enhance graft-versus-malignancy effects.
allogeneic transplants are feasible in elderly patients with acceptable toxicity and GVHD rates. Favourable outcome is expected when the disease is in remission at the time of transplant. Giralt et al (1997c) reported a second study combining melphalan (180 mg/m 2 ) and fludarabine (125 mg/m 2 ) for treatment of advanced acute leukaemia; this regimen is sufficiently immunosuppressive to allow for engraftment in unrelated or one HLA-disparate related transplants. Patients with refractory relapse usually recurred, but 56% of patients with chemotherapy-sensitive disease remained in continuous remission beyond 1 year. Slavin et al (1998) reported use of a reduced toxicity preparative regimen consisting of busulphan 8 mg/kg, fludarabine and anti-thymocyte globulin. Although less intensive and less toxic than commonly used ablative preparative regimens, this regimen produces marked myelosuppression and has not been administered without haematopoietic transplantation. Another innovative approach involves low doses of total body irradiation (TBI) (2 Gy) that is minimally myelosuppressive but that allows engraftment in a high fraction of patients (Storb et al, 1999a,b) ; patients have achieved initial mixed chimaerism and subsequent graft-versus-leukaemia effects (McSweeney et al, 1999) . Other reduced toxicity or non-ablative regimens have been proposed (Kelemen et al, 1998; Khoury et al, 1999; Sykes et al, 1999) .
Indolent lymphoid malignancies also appear to be amenable to this strategy. Khouri et al (1998) treated 15 heavily pretreated patients with CLL or lymphoma using a non-myeloablative regimen of fludarabine and cyclophosphamide or fludarabine, cytarabine and cisplatin. All patients had failed to respond or recurred after primary chemotherapy. Nine patients had CLL in relapse after prior fludarabine treatment and six patients had lymphoma. Eleven of the 15 patients had durable engraftment, with 50±100% donor cells at 1 month after transplant, typically converting to 100% over the next 2 months spontaneously or after infusion of additional donor lymphocytes. Haematopoietic recovery was prompt and, with the exception of a patient with hepatitis C infection, no patient had nonhaematological toxicity of greater than grade 2. The patients failing to engraft recovered endogenous haematopoiesis promptly and had no serious adverse effects. All 11 patients with engraftment have responded and eight have achieved complete remission. Maximal responses were slow to develop and gradually occured over a period of several months to 1 year. Extending these studies to low-grade lymphoma, 11 patients received fludarabine 25 mg/m 2 for 5 d with cyclophosphamide 1 gm/m 2 on days 4 and 5, followed by allogeneic blood stem cell transplantation. This produced minimal toxicity and a median of 6 d with neutropenia. All 11 patients achieved engraftment and complete remission with no treatment-related mortality (Khouri et al, 1999a) . This compares favourably with highdose cyclophosphamide±total body irradiation regimens in which treatment-related mortality rates are typically . 30% ). Hodgkin's disease (Anderlini et al, 2000; Carella et al, 2000) and mantle cell lymphoma (Khouri et al, 1999b) have also been successfully treated with non-ablative allogeneic transplants.
Allogeneic bone marrow transplantation is associated with a high risk of treatment-related mortality in multiple myeloma, up to 70% in some series (Gahrton et al, 1995; Bensinger et al, 1996) . The strategy of a non-ablative preparative regimen may reduce this morbidity while still harnessing a graft-versus-myeloma effect. Giralt et al (1999) explored a regimen of melphalan (140 mg/m 2 ) and fludarabine (30 mg/m 2 for 4 d). Seven of 13 patients with far advanced myeloma have achieved complete remission. This promising approach requires further study.
Indications for a non-myeloablative preparative regimen
The use of non-ablative regimens is not appropriate in many settings. This strategy is only useful in diseases susceptible to graft-versus-malignancy effects. Success also requires development of an effective GVL effect before the underlying disease can progress. This approach has generally been unsuccessful in patients with active aggressive malignancies, such as refractory acute leukaemias (Giralt et al, 1997b) . In these cases, the malignancy may recur rapidly after a non-ablative regimen, outpacing generation of graftversus-malignancy effects. Non-ablative regimens may be useful, however, for consolidation of remission in AML patients at high risk of relapse. Indolent malignancies that are not immediately life threatening appear to be the best candidates for this strategy; responses developing over several months can be effective in relatively stable patients with CML in chronic phase or low-grade lymphoid malignancies.
The optimal intensity of the preparative regimen depends on several factors, including the disease status, the aggressiveness of the patient's malignancy, the immunocompetence of the recipient and histocompatibility differences between the donor and recipient. Immunocompromised patients, such as those with advanced CLL, require less intensive immunosuppressive therapy to achieve engraftment than a fully immunocompetent recipient. Non-ablative regimens have generally been studied in patients with an HLA-identical sibling donor. Greater immunosuppression will be required for engraftment of HLA-non-identical or unrelated transplants.
Indolent malignancies may not require major cytoreduction, but more intensive treatment is necessary to achieve at least a short-term remission in patients with highly proliferative malignancies, such as acute leukaemias and aggressive lymphomas, to allow development of an effective GVL response.
The optimal post-transplant immunosuppressive therapy is also uncertain. Acute GVHD does occur with these nonablative regimens, but has been relatively mild and controllable. Immunosuppressive therapy given early after transplant to prevent GVHD probably also inhibits GVL (Bacigalupo et al, 1991) . The indications for donor lymphocyte infusions need to be clarified. Effective strategies to separate GVHD from GVL are critical for the success of this approach to treatment.
In conclusion, the immune graft-versus-malignancy effect is potentially curative without high-dose chemotherapy for susceptible malignancies. Use of less toxic, non-myeloablative preparative regimens allows engraftment and generation of graft-versus-malignancy effects. This approach will reduce the risks of treatment-related morbidity and allow the use of allotransplantation for older patients and those with co-morbidities that preclude high-dose chemoradiotherapy.
The indications for a non-myeloablative versus high-dose ablative preparative regimen need to be defined. The benefit of reduced toxicity with non-ablative regimens may be offset by loss of the major cytoreduction induced by high-dose chemotherapy. At present, young patients with myeloid malignancies in good physical condition have established benefits with high-dose ablative transplant regimens and non-ablative regimens might best be studied in patients over the age of 55 years or with major medical co-morbidities. The role of allogeneic haematopoietic transplantation is less established in the indolent lymphoid malignancies and the encouraging data reported above support further testing, even in young patients. Patients should only be treated in the context of clinical trials designed to address outstanding issues with this approach. Ultimately, controlled trials are needed to define the relative efficacy of this strategy compared with alternative forms of transplantation, as well as standard chemotherapy treatments. 
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